United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA

 United Therapeutics Announces Receipt Of Second Complete Response Letter For
                            Oral Treprostinil NDA

PR Newswire

SILVER SPRING, Md., March 25, 2013

SILVER SPRING, Md., March 25, 2013 /PRNewswire/ --United Therapeutics
Corporation (NASDAQ: UTHR) announced today that it received a second complete
response letter from the United States Food and Drug Administration (FDA)
declining to approve its new drug application (NDA) for treprostinil diolamine
extended release tablets (oral treprostinil) for the treatment of pulmonary
arterial hypertension (PAH).

Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United
Therapeutics commented, "We remain confident that oral treprostinil will play
an important role in treating PAH and we are committed to working
collaboratively with the FDA to accomplish this goal in the most timely and
appropriate manner."

United Therapeutics intends to immediately request an "end of review" meeting
with the FDA to discuss this complete response letter.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the
development and commercialization of unique products to address the unmet
medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include, among
others, statements regarding United Therapeutics' future efforts to gain
approval of oral treprostinil, the related timing of those efforts, and
actions United Therapeutics may take in response to the FDA's complete
response letter. These forward-looking statements are subject to certain
risks and uncertainties, such as those described in our periodic reports filed
with the Securities and Exchange Commission, that could cause actual results
to differ materially from anticipated results.Consequently, such
forward-looking statements are qualified by the cautionary statements,
cautionary language and risk factors set forth in our periodic reports and
documents filed with the Securities and Exchange Commission, including our
most recent Annual Report on Form10-K, Quarterly Reports on Form10-Q, and
Current Reports on Form8-K. We claim the protection of the safe harbor
contained in the Private Securities Litigation Reform Act of 1995 for
forward-looking statements. We are providing this information as of March 25,
2013, and assume no obligation to update or revise the information contained
in this press release whether as a result of new information, future events or
any other reason. [uthr-g]

SOURCE United Therapeutics Corporation

Contact: Andrew Fisher, (202) 483-7000, Afisher@unither.com